Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.11 USD
Change Today -0.22 / -0.47%
Volume 676.0K
AKRX On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

akorn inc (AKRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $57.10
52 Week Low
08/6/14 - $31.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AKORN INC (AKRX)

akorn inc (AKRX) Related Businessweek News

No Related Businessweek News Found

akorn inc (AKRX) Details

Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segment’s generic products include Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products. The Consumer Health segment markets branded and private label animal health products, as well as OTC products for the treatment of dry eye under the TheraTears brand name. This segment’s branded products comprise Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; Nembutal, a sedative; and Xopenex inhalation solution for the treatment or prevention of bronchospasm. It also markets other OTC consumer health products, including Mag-Ox, a diabetes magnesium supplement, and the Zostrix brand of capsaicin products for pain management; and animal health branded and generic products comprising Anased, Tolazine, Yobine, Butorphic, and VetaKet. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

1,644 Employees
Last Reported Date: 03/17/15
Founded in 1971

akorn inc (AKRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $1.1M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $384.0K
Chief Operating Officer
Total Annual Compensation: $423.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $349.1K
Senior Vice President of National Accounts an...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

akorn inc (AKRX) Key Developments

Knight Therapeutics Inc. Signs Exclusive Distribution Agreement with Akorn, Inc

Knight Therapeutics Inc. announced the signing of an agreement with Akorn, Inc. for the exclusive distribution of AzaSite(r) in Canadian markets. Under the terms of the agreement with Akorn, Knight will handle all regulatory and commercial activities for AzaSite(r) in Canada.

Akorn Announces Nasdaq's Acceptance of Its Plan to Regain Compliance

Akorn, Inc. announced that the Nasdaq Stock Market has accepted the company's plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) which will permit the continued listing of Akorn's stock on the Nasdaq Global Select Market. As previously reported on May 18, 2015, Akorn received a letter from Nasdaq stating that the company was not in compliance with Nasdaq listing rules because the company had not filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015 with the Securities and Exchange Commission. In the letter, Nasdaq requested that Akorn submit a plan to regain compliance with Nasdaq listing rules within 60 days. On July 10, 2015, Akorn submitted to Nasdaq a plan to regain compliance with Nasdaq listing rules. After reviewing Akorn's plan to regain compliance, Nasdaq granted an exception to enable the company to regain compliance with the listing rules. Under the terms of the exception, Akorn must file its Form 10-Q for the quarterly period ended March 31, 2015 and all other periodic reports required by listing rules on or before November 9, 2015. In the event that Akorn does not satisfy the terms set forth in the extension, Nasdaq will provide written notification that Akorn's securities will be subject to delisting proceedings. At that time, Akorn may appeal Nasdaq's determination for a panel review.

Akorn, Inc. Launches Acetylcysteine Injection

Akorn, Inc. announced that it has launched Acetylcysteine Injection 6 g/30 mL in 30 mL single-dose vials. The launch follows an approval of an abbreviated new drug application (ANDA) for the product from the U.S. Food and Drug Administration (FDA) on March 24, 2015. Akorn's product is therapeutically equivalent to Acetadote® injection marketed by Cumberland Pharmaceuticals Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKRX:US $46.11 USD -0.22

AKRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Impax Laboratories Inc $48.46 USD +0.10
Lannett Co Inc $59.60 USD +0.16
Pacira Pharmaceuticals Inc/DE $66.42 USD +4.62
Prestige Brands Holdings Inc $47.62 USD +0.21
Taro Pharmaceutical Industries Ltd $139.35 USD +0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation AKRX Industry Range
Price/Earnings 100.0x
Price/Sales 8.4x
Price/Book 13.3x
Price/Cash Flow 66.4x
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKORN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at